June 15, 2026 10:45 Regulatory Bulletin from the extraordinary general meeting of Flerie AB (publ) on 15 June 2026 at 10:00 CEST Read news release
June 5, 2026 Flerie’s portfolio company Xspray Pharma receives CRL from FDA for Nilopki™ Read news release
June 5, 2026 Flerie’s portfolio company Xspray Pharma receives CRL from FDA for Nilopki™ Read news release
June 1, 2026 Flerie’s portfolio company Xintela presents positive results from clinical study with its stem cell product XSTEM Read news release
May 20, 2026 Flerie’s portfolio company Prokarium presents positive interim data from clinical study in bladder cancer Read news release